Hypertension as an autoimmune and inflammatory disease

Hypertension Research

Volumn 39, Issue 8, 2016, Pages 567-573

  Solak, Yalcin ^a   Afsar, Baris ^b   Vaziri, Nosratola D ^c   Aslan, Gamze ^d   Yalcin, Can Ege ^d   Covic, Adrian ^e   Kanbay, Mehmet ^d  

^a SAKARYA UNIVERSITY   (Turkey)

^b Konya Numune State Hospital   (Turkey)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KOÇ UNIVERSITY   (Turkey)

^e GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

autoimmune disease; inflammation

Indexed keywords

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE COURSE; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; INTESTINE FLORA; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; ANIMAL; INFLAMMATION; KIDNEY; METABOLISM; PHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; HYPERTENSION; INFLAMMATION; KIDNEY; OXIDATIVE STRESS;

EID: 84982789672     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.35     Document Type: Review

References (78)

1. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, Park JR, Kim SW. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433.
2. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-Alpha) and essential hypertension. J Hum Hypertens 2005; 19: 149-154.
3. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861.
4. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
5. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007; 49: 304-310.
6. King DE, Egan BM, Mainous AG III, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich) 2004; 6: 562-568.
7. Mattace-Raso FU, Verwoert GC, Hofman A, Witteman JC. Inflammation and incidentisolated systolic hypertension in older adults: The Rotterdam study. J Hypertens 2010; 28: 892-895.
8. Bendich A, Belisle EH, Strausser HR. Immune system modulation and its effect on the blood pressure of the spontaneously hypertensive male and female rat. Biochem Biophys Res Commun 1981; 99: 600-607.
9. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol 2004; 286: F606-F616.
10. Heijnen BF, Van Essen H, Schalkwijk CG, Janssen BJ, Struijker-Boudier HA. Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Hypertens Res 2014; 37: 100-109.
11. Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, Vaziri ND. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 2003; 41: 341-346.
12. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension 2011; 57: 132-140.
13. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191-F201.
14. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gómez-Garre D, Largo R, Egido J, Johnson RJ, Rodríguez-Iturbe B. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001; 281: F38-F47.
15. Rodriguez-Iturbe B, Franco M, Johnson RJ. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. Curr Opin Nephrol Hypertens 2013; 22: 37-44.
16. Tinsley JH, South S, Chiasson VL, Mitchell BM. Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure in hypertensive pregnant rats. Am J Physiol Regulat Integr Compar Physiol 2010; 298: R713-R719.
17. Dhande I, Ma W, Hussain T. Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-Activated THP-1 macrophages via increased interleukin-10 production. Hypertens Res 2015; 38: 21-29.
18. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106-2113.
19. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Mönzel T. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124: 1370-1381.
20. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-1122.
21. Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K, Stefanadis C. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231-2238.
22. Zheng X, Jin C, Liu Y, Zhang J, Zhu Y, Kan S, Wu Y, Ruan C, Lin L, Yang X, Zhao X, Wu S. Arterial stiffness as a predictor of clinical hypertension. J Clin Hypertens (Greenwich) 2015; 17: 582-591.
23. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012; 308: 875-881.
24. Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz RM. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol 2015; 31: 631-641.
25. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-274.
26. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003; 42: 811-817.
27. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, Díez J. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-1061.
28. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011; 15: 1583-1606.
29. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 2013; 305: H1417-H1427.
30. Rodrigo R, Libuy M, Feliu F, Hasson D. Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. Dis Markers 2013; 35: 773-790.
31. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: Association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004; 36: 226-232.
32. Gonzalez J, Valls N, Brito R, Rodrigo R. Essential hypertension and oxidative stress: new insights. World J Cardiol 2014; 6: 353-366.
33. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923.
34. Makino A, Skelton MM, Zou AP, Roman RJ, Cowley AW Jr. Increased renal medullary oxidative stress produces hypertension. Hypertension 2002; 39 (Part 2): 667-672.
35. Javkhedkar AA, Banday AA. Antioxidant resveratrol restores renal sodium transport regulation in SHR. Physiol Rep 2015; 3: 11.
36. Miyashita H, Chikazawa M, Otaki N, Hioki Y, Shimozu Y, Nakashima F, Shibata T, Hagihara Y, Maruyama S, Matsumi N, Uchida K. Lysine pyrrolation is a naturallyoccurring covalent modification involved in the production of DNA mimic proteins. Sci Rep 2014; 4: 5343.
37. Wu J, Saleh MA, Kirabo A, Itani HA, Montaniel KR, Xiao L, Chen W, Mernaugh RL, Cai H, Bernstein KE, Goronzy JJ, Weyand CM, Curci JA, Barbaro NR, Moreno H, Davies SS, Roberts LJ II, Madhur MS, Harrison DG. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest 2015; 126: 50-67.
38. Harrison DG. The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 2013; 7: 68-74.
39. Eslami S, Sahebkar A. Glutathione-S-Transferase M1 and T1 null genotypes are associated with hypertension risk: A systematic review and meta-Analysis of 12 studies. Curr Hypertens Rep 2014; 16: 432.
40. Rafiq A, Aslam K, Malik R, Afroze D. C242T polymorphism of the NADPH oxidase p22PHOX gene and its association with endothelial dysfunction in asymptomatic individuals with essential systemic hypertension. Mol Med Rep 2014; 9: 1857-1862.
41. Hong EP, Kim DH, Suh JG, Park JW. Genetic risk assessment for cardiovascular disease with seven genes associated with plasma C-reactive protein concentrations in Asian populations. Hypertens Res 2014; 37: 692-698.
42. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-2460.
43. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-507.
44. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011; 57: 469-476.
45. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosteroneinduced vascular injury. Hypertension 2012; 59: 324-330.
46. Rodriguez-Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. Autoimmunity in the pathogenesis of hypertension. Nat Rev Nephrol 2014; 10: 56-62.
47. Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Johnson RJ, Rodriguez-Iturbe B. Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int Suppl 2008; 111: S55-S59.
48. Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Renal Physiol 2013; 304: F289-F299.
49. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, Muller DN, Hafler DA. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013; 496: 518-522.
50. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP, Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960.
51. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Möller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009; 15: 545-552.
52. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17 (Suppl 3): S218-S225.
53. Li JX, Tang BP, Sun HP, Feng M, Cheng ZH, Niu WQ. Interacting contribution of the five polymorphisms in three genes of Hsp70 family to essential hypertension in Uygur ethnicity. Cell Stress Chaperones 2009; 14: 355-362.
54. Xu Q, Fawcett TW, Udelsman R, Holbrook NJ. Activation of heat shock transcription factor 1 in rat aorta in response to high blood pressure. Hypertension 1996; 28: 53-57.
55. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
56. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 2015; 24: 403-409.
57. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331-1340.
58. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003; 77: 326-330.
59. Menni C, Mangino M, Cecelja M, Psatha M, Brosnan MJ, Trimmer J, Mohney RP, Chowienczyk P, Padmanabhan S, Spector TD, Valdes AM. Metabolomic study of carotid-femoral pulse-wave velocity in women. J Hypertens 2015; 33: 791-796.
60. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: A systematic review and meta-Analysis of randomized, controlled trials. Hypertension 2014; 64: 897-903.
61. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657-670.
62. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
63. Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 2014; 5: 202-207.
64. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T, Firestein SJ, Yanagisawa M, Gordon JI, Eichmann A, Peti-Peterdi J, Caplan MJ. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013; 110: 4410-4415.
65. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology 2012; 17: 733-738.
66. Shi K, Wang F, Jiang H, Liu H, Wei M, Wang Z, Xie L. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59: 2109-2117.
67. Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D, Shah V, Dwivedi R, Becker K, Kovesdy CP, Raj DS. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Renal Nutr 2012; 22: 317-326.
68. Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-Aged men and women. Coronary Artery Dis 2004; 15: 331-336.
69. Kashyap MK, Yadav V, Sherawat BS, Jain S, Kumari S, Khullar M, Sharma PC, Nath R. Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005; 277: 89-99.
70. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: The CARDIA study. Arch Intern Med 2006; 166: 345-349.
71. Rodrigo R, Bächler JP, Araya J, Prat H, Passalacqua W. Relationship between (Na+ K)-ATPase activity, lipid peroxidation and fatty acid profile in erythrocytes of hypertensive and normotensive subjects. Mol Cell Biochem 2007; 303: 73-81.
72. Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bachler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007; 30: 1159.
73. Rodrigo R, Prat H, Passalacqua W, Araya J, Bächler JP. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci 2008; 114: 625-634.
74. Sahakyan K, Klein BE, Myers CE, Tsai MY, Klein R. Novel risk factors in long-Term hypertension incidence in type 1 diabetes mellitus. Am Heart J 2010; 159: 1074-1080.
75. Wang L, Manson JE, Gaziano JM, Liu S, Cochrane B, Cook NR, Ridker PM, Rifai N, Sesso HD. Circulating inflammatory and endothelial markers and risk of hypertension in white and black postmenopausal women. Clin Chem 2011; 57: 729-736.
76. Chuang S-Y, Hsu P-F, Chang H-Y, Bai C-H, Yeh W-T, Pan H-W. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: The Cardiovascular Disease Risk Factors Two-Township Study. Am J Hypertens 2013; 26: 657-664.
77. Yao W, Sun Y, Wang X, Niu K. Elevated serum level of interleukin 17 in a population with prehypertension. J Clin Hypertens 2015; 17: 770-774.
78. Sesso HD, Jiménez MC, Wang L, Ridker PM, Buring JE, Gaziano JM. Plasma inflammatory markers and the risk of developing hypertension in men. J Am Heart Assoc 2015; 4: e001802.